Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade

Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade Introduction

Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade is a novel biosimilar antibody that targets the therapeutic protein BIT (Biosimilar Inhibitor of Tumorigenesis). This biosimilar antibody is designed to mimic the activity of the original anti-BIT monoclonal antibody (mAb) in terms of structure, function, and application. In this article, we will discuss the structure, activity, and potential applications of Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade.

Structure

Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade is a recombinant monoclonal antibody that is produced in a mammalian expression system. It is composed of two heavy chains and two light chains, each consisting of variable and constant regions. The variable regions of the antibody are responsible for binding to the target protein, BIT, while the constant regions provide stability and effector functions.

The amino acid sequence of Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade is highly similar to the original anti-BIT mAb, ensuring its ability to bind to the same epitope on the BIT protein. This similarity also makes it a suitable replacement for the original antibody, with minimal risk of immunogenicity or adverse reactions.

Activity

Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade has been shown to exhibit similar activity to the original anti-BIT mAb in various in vitro and in vivo studies. It binds to the BIT protein with high affinity, inhibiting its interaction with its receptor and thereby blocking its downstream signaling pathways.

This inhibition of BIT activity has been shown to have anti-tumorigenic effects, making Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade a potential therapeutic agent for various cancers. It has also been shown to have anti-inflammatory properties, making it a promising candidate for the treatment of autoimmune diseases.

Applications

The primary application of Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade is in the treatment of cancers and autoimmune diseases. Its ability to inhibit BIT activity makes it a potential therapeutic agent for a wide range of cancers, including breast, lung, and colon cancer. It can also be used to treat autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

In addition to its potential as a therapeutic agent, Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade can also be used as a research tool in various studies related to the BIT protein. Its high specificity and affinity for BIT make it a valuable tool for studying the role of this protein in various disease processes.

Conclusion

Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade is a biosimilar antibody that targets the therapeutic protein BIT. Its structure and activity closely resemble that of the original anti-BIT mAb, making it a suitable replacement for this antibody. With its potential applications in cancer and autoimmune disease treatment, as well as its use as a research tool, Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade shows great promise in the field of biopharmaceuticals.

ProteoGenix catalogue number PX-TA2044. For research use only.

Target: Anzurstobart Biosimilar – Anti-BIT mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet